Artivion, Inc. AORT

NYSE · Approved · cardio-renal-metabolic · device-combination · EDGAR · Updated Nov 7, 2026

Artivion, Inc. (NYSE: AORT) is a cardio-renal-metabolic drug developer. Its lead program, NEXUS family of products (aortic arch stent graft systems), is marketed for Aortic disease / aortic arch reconstruction.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Pipeline

Program	Indication	Modality	Stage
NEXUS ONE / NEXUS DUO / NEXUS TRE aortic arch stent grafts	Aortic arch disease	device-combination	Approved
AMDS Hybrid Prosthesis	Acute DeBakey Type I dissections in the presence of malperfusion	device-combination	Approved
E-vita Open NEO / E-vita Open Plus	Aortic arch disease	device-combination	Approved
Arcevo LSA aortic arch stent graft	Aortic arch disease	device-combination	Approved
On-X aortic and mitral heart valves	Heart valve replacement	device-combination	Approved
BioGlue Surgical Adhesive	Hemostasis adjunct in large vessel repair	biologic-other	Approved
E-xtra Design Engineering / E-nside / Artivex abdominal stent grafts	Abdominal aortic disease	device-combination	Approved
PhotoFix bovine surgical patches	Surgical reconstruction	biologic-other	Approved
CarbonAid CO2 diffusion catheters	Cardiac surgery adjunct	device-combination	Approved
Cardiac and vascular tissue processing (preservation services)	Cardiac/vascular reconstruction	biologic-other	Approved

For subscribers

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export

See plans Open in the tracker

Artivion, Inc. AORT

Upcoming catalysts

Pipeline

Recent results and decisions

For subscribers

Other approved cardio-renal-metabolic companies

The free Monday brief